[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f1lMn28gGsgXzjiEq8sDhH-t1DLmY_SkKDK5S6ZGJM-M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":40,"rows":47},"The University of New South Wales",[4],66,false,5,7,8954,2,49,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Depression",9,{"name":18,"count":19},"Major Depression",8,{"name":21,"count":22},"Bipolar Disorder",4,{"name":24,"count":25},"Major Depressive Disorder",3,{"name":27,"count":11},"Psychotic Disorder",{"name":29,"count":11},"Behavior, Addictive",{"name":31,"count":11},"Dry Eye Syndromes",{"name":33,"count":11},"Osteoarthritis",[35],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06898853","The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes","2026-12-30","0.1% Ciclosporin A eye drops",[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,73,91,118,144,162,180,211,251,269,287,305,323,341,359,377,395,413,431,449,467,485,503,530,562,599,632,657,680,704,722,746],{"intervention":39,"totalTrials":49,"cells":50},1,{"EARLY_PHASE1":51,"PHASE1":54,"PHASE2":56,"PHASE3":58,"PHASE4":60,"NA":62},{"trials":52,"activeCount":53},[],0,{"trials":55,"activeCount":53},[],{"trials":57,"activeCount":53},[],{"trials":59,"activeCount":53},[],{"trials":61,"activeCount":53},[],{"trials":63,"activeCount":49,"soonestReadout":38},[64],{"nctId":36,"briefTitle":37,"status":65,"phases":66,"primaryCompletion":38,"completion":38,"start":67,"enrollment":68,"conditions":69,"interventions":71},"RECRUITING",[46],"2025-06-01",60,[70],"Dry Eye Disease (DED)",[39,72],"Mineral oils eye drops",{"intervention":72,"totalTrials":49,"cells":74},{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":85},{"trials":76,"activeCount":53},[],{"trials":78,"activeCount":53},[],{"trials":80,"activeCount":53},[],{"trials":82,"activeCount":53},[],{"trials":84,"activeCount":53},[],{"trials":86,"activeCount":49,"soonestReadout":38},[87],{"nctId":36,"briefTitle":37,"status":65,"phases":88,"primaryCompletion":38,"completion":38,"start":67,"enrollment":68,"conditions":89,"interventions":90},[46],[70],[39,72],{"intervention":92,"totalTrials":49,"cells":93},"Rosiglitazone",{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":116},{"trials":95,"activeCount":53},[],{"trials":97,"activeCount":53},[],{"trials":99,"activeCount":53},[],{"trials":101,"activeCount":53},[],{"trials":103,"activeCount":53},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":115},"NCT00372086","Rosiglitazone and Insulin in T1DM Adolescents","COMPLETED",[45],"2005-09","2003-08",32,[113,114],"Type 1 Diabetes","Puberty: >Tanner 2 Breast Development or Testis >4ml",[92],{"trials":117,"activeCount":53},[],{"intervention":119,"totalTrials":49,"cells":120},"Omega 3",{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":140,"NA":142},{"trials":122,"activeCount":53},[],{"trials":124,"activeCount":53},[],{"trials":126,"activeCount":53},[],{"trials":128,"activeCount":53},[129],{"nctId":130,"briefTitle":131,"status":107,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT02871440","A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye",[44],"2017-09-18","2016-09-19",40,[31],[119,138,139],"Optive Advanced","Optive",{"trials":141,"activeCount":53},[],{"trials":143,"activeCount":53},[],{"intervention":138,"totalTrials":49,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":158,"NA":160},{"trials":147,"activeCount":53},[],{"trials":149,"activeCount":53},[],{"trials":151,"activeCount":53},[],{"trials":153,"activeCount":53},[154],{"nctId":130,"briefTitle":131,"status":107,"phases":155,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":156,"interventions":157},[44],[31],[119,138,139],{"trials":159,"activeCount":53},[],{"trials":161,"activeCount":53},[],{"intervention":139,"totalTrials":49,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":176,"NA":178},{"trials":165,"activeCount":53},[],{"trials":167,"activeCount":53},[],{"trials":169,"activeCount":53},[],{"trials":171,"activeCount":53},[172],{"nctId":130,"briefTitle":131,"status":107,"phases":173,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":174,"interventions":175},[44],[31],[119,138,139],{"trials":177,"activeCount":53},[],{"trials":179,"activeCount":53},[],{"intervention":181,"totalTrials":49,"cells":182},"Quadrivalent HPV vaccine",{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":207,"NA":209},{"trials":184,"activeCount":53},[],{"trials":186,"activeCount":53},[],{"trials":188,"activeCount":53},[],{"trials":190,"activeCount":53},[191],{"nctId":192,"briefTitle":193,"status":107,"phases":194,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":206},"NCT02263703","Immunogenicity of HPV Vaccine in Immunosuppressed Children",[44],"2016-02","2016-12","2007-05",55,[200,201,202,203,204,205],"Autoimmune Disease","Juvenile Idiopathic Arthritis","Inflammatory Bowel Disease","Evidence of Liver Transplantation","Kidney Transplant Infection","Bone Marrow Transplant Infection",[181],{"trials":208,"activeCount":53},[],{"trials":210,"activeCount":53},[],{"intervention":212,"totalTrials":49,"cells":213},"alemtuzumab",{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":247,"NA":249},{"trials":215,"activeCount":53},[],{"trials":217,"activeCount":53},[],{"trials":219,"activeCount":53},[],{"trials":221,"activeCount":53},[222],{"nctId":223,"briefTitle":224,"status":107,"phases":225,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":229,"interventions":232},"NCT00454480","Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",[43,44],"2012-08","2006-08",2000,[230,231],"Leukemia","Myelodysplastic Syndromes",[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],"arsenic trioxide","azacitidine","busulfan","clofarabine","cytarabine","daunorubicin hydrochloride","fludarabine phosphate","gemtuzumab ozogamicin","melphalan","tipifarnib","DNA methylation analysis","cytogenetic analysis","gene expression analysis","mutation analysis",{"trials":248,"activeCount":53},[],{"trials":250,"activeCount":53},[],{"intervention":233,"totalTrials":49,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":265,"NA":267},{"trials":254,"activeCount":53},[],{"trials":256,"activeCount":53},[],{"trials":258,"activeCount":53},[],{"trials":260,"activeCount":53},[261],{"nctId":223,"briefTitle":224,"status":107,"phases":262,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":263,"interventions":264},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":266,"activeCount":53},[],{"trials":268,"activeCount":53},[],{"intervention":234,"totalTrials":49,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":283,"NA":285},{"trials":272,"activeCount":53},[],{"trials":274,"activeCount":53},[],{"trials":276,"activeCount":53},[],{"trials":278,"activeCount":53},[279],{"nctId":223,"briefTitle":224,"status":107,"phases":280,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":281,"interventions":282},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":284,"activeCount":53},[],{"trials":286,"activeCount":53},[],{"intervention":235,"totalTrials":49,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":301,"NA":303},{"trials":290,"activeCount":53},[],{"trials":292,"activeCount":53},[],{"trials":294,"activeCount":53},[],{"trials":296,"activeCount":53},[297],{"nctId":223,"briefTitle":224,"status":107,"phases":298,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":299,"interventions":300},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":302,"activeCount":53},[],{"trials":304,"activeCount":53},[],{"intervention":236,"totalTrials":49,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":319,"NA":321},{"trials":308,"activeCount":53},[],{"trials":310,"activeCount":53},[],{"trials":312,"activeCount":53},[],{"trials":314,"activeCount":53},[315],{"nctId":223,"briefTitle":224,"status":107,"phases":316,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":317,"interventions":318},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":320,"activeCount":53},[],{"trials":322,"activeCount":53},[],{"intervention":237,"totalTrials":49,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":337,"NA":339},{"trials":326,"activeCount":53},[],{"trials":328,"activeCount":53},[],{"trials":330,"activeCount":53},[],{"trials":332,"activeCount":53},[333],{"nctId":223,"briefTitle":224,"status":107,"phases":334,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":335,"interventions":336},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":338,"activeCount":53},[],{"trials":340,"activeCount":53},[],{"intervention":238,"totalTrials":49,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":355,"NA":357},{"trials":344,"activeCount":53},[],{"trials":346,"activeCount":53},[],{"trials":348,"activeCount":53},[],{"trials":350,"activeCount":53},[351],{"nctId":223,"briefTitle":224,"status":107,"phases":352,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":353,"interventions":354},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":356,"activeCount":53},[],{"trials":358,"activeCount":53},[],{"intervention":239,"totalTrials":49,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":373,"NA":375},{"trials":362,"activeCount":53},[],{"trials":364,"activeCount":53},[],{"trials":366,"activeCount":53},[],{"trials":368,"activeCount":53},[369],{"nctId":223,"briefTitle":224,"status":107,"phases":370,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":371,"interventions":372},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":374,"activeCount":53},[],{"trials":376,"activeCount":53},[],{"intervention":240,"totalTrials":49,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":391,"NA":393},{"trials":380,"activeCount":53},[],{"trials":382,"activeCount":53},[],{"trials":384,"activeCount":53},[],{"trials":386,"activeCount":53},[387],{"nctId":223,"briefTitle":224,"status":107,"phases":388,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":389,"interventions":390},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":392,"activeCount":53},[],{"trials":394,"activeCount":53},[],{"intervention":241,"totalTrials":49,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":409,"NA":411},{"trials":398,"activeCount":53},[],{"trials":400,"activeCount":53},[],{"trials":402,"activeCount":53},[],{"trials":404,"activeCount":53},[405],{"nctId":223,"briefTitle":224,"status":107,"phases":406,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":407,"interventions":408},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":410,"activeCount":53},[],{"trials":412,"activeCount":53},[],{"intervention":242,"totalTrials":49,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":427,"NA":429},{"trials":416,"activeCount":53},[],{"trials":418,"activeCount":53},[],{"trials":420,"activeCount":53},[],{"trials":422,"activeCount":53},[423],{"nctId":223,"briefTitle":224,"status":107,"phases":424,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":425,"interventions":426},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":428,"activeCount":53},[],{"trials":430,"activeCount":53},[],{"intervention":243,"totalTrials":49,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":445,"NA":447},{"trials":434,"activeCount":53},[],{"trials":436,"activeCount":53},[],{"trials":438,"activeCount":53},[],{"trials":440,"activeCount":53},[441],{"nctId":223,"briefTitle":224,"status":107,"phases":442,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":443,"interventions":444},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":446,"activeCount":53},[],{"trials":448,"activeCount":53},[],{"intervention":244,"totalTrials":49,"cells":450},{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":463,"NA":465},{"trials":452,"activeCount":53},[],{"trials":454,"activeCount":53},[],{"trials":456,"activeCount":53},[],{"trials":458,"activeCount":53},[459],{"nctId":223,"briefTitle":224,"status":107,"phases":460,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":461,"interventions":462},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":464,"activeCount":53},[],{"trials":466,"activeCount":53},[],{"intervention":245,"totalTrials":49,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":481,"NA":483},{"trials":470,"activeCount":53},[],{"trials":472,"activeCount":53},[],{"trials":474,"activeCount":53},[],{"trials":476,"activeCount":53},[477],{"nctId":223,"briefTitle":224,"status":107,"phases":478,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":479,"interventions":480},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":482,"activeCount":53},[],{"trials":484,"activeCount":53},[],{"intervention":246,"totalTrials":49,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":499,"NA":501},{"trials":488,"activeCount":53},[],{"trials":490,"activeCount":53},[],{"trials":492,"activeCount":53},[],{"trials":494,"activeCount":53},[495],{"nctId":223,"briefTitle":224,"status":107,"phases":496,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":497,"interventions":498},[43,44],[230,231],[212,233,234,235,236,237,238,239,240,241,242,243,244,245,246],{"trials":500,"activeCount":53},[],{"trials":502,"activeCount":53},[],{"intervention":504,"totalTrials":49,"cells":505},"RBP-6000",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":526,"NA":528},{"trials":507,"activeCount":53},[],{"trials":509,"activeCount":53},[],{"trials":511,"activeCount":53},[],{"trials":513,"activeCount":53},[514],{"nctId":515,"briefTitle":516,"status":517,"phases":518,"primaryCompletion":519,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT03809143","Community Studies of Long Acting Buprenorphine (CoLAB)","UNKNOWN",[44],"2020-11-01","2021-03-30","2019-05-22",100,[524],"Opioid Dependence",[504],{"trials":527,"activeCount":53},[],{"trials":529,"activeCount":53},[],{"intervention":531,"totalTrials":11,"cells":532},"Omega-3 Polyunsaturated Fatty Acids",{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":534,"activeCount":53},[],{"trials":536,"activeCount":53},[],{"trials":538,"activeCount":53},[539,548],{"nctId":540,"briefTitle":541,"status":517,"phases":542,"start":543,"enrollment":544,"conditions":545,"interventions":547},"NCT00238758","A Study of Omega-3 as a Treatment for Major Depression",[43],"2005-10",128,[18,546],"Dysthymia",[531],{"nctId":549,"briefTitle":550,"status":517,"phases":551,"start":552,"enrollment":553,"conditions":554,"interventions":555},"NCT00289484","A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression",[43],"2006-02",52,[18],[531],{"trials":557,"activeCount":53},[],{"trials":559,"activeCount":53},[],{"trials":561,"activeCount":53},[],{"intervention":563,"totalTrials":11,"cells":564},"Ketamine",{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":580,"PHASE3":593,"PHASE4":595,"NA":597},{"trials":566,"activeCount":53},[],{"trials":568,"activeCount":53},[569],{"nctId":570,"briefTitle":571,"status":107,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":579},"NCT02401139","Ketamine Trial for the Treatment of Depression",[42],"2015-07","2015-09","2015-03",10,[578],"Unipolar Depression",[563],{"trials":581,"activeCount":53},[582],{"nctId":583,"briefTitle":584,"status":517,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":591},"NCT01441505","A Study of Ketamine as an Antidepressant",[43],"2014-12","2011-09",42,[590],"Major Depressive Episode",[563,592],"Saline or Midazolam",{"trials":594,"activeCount":53},[],{"trials":596,"activeCount":53},[],{"trials":598,"activeCount":53},[],{"intervention":600,"totalTrials":11,"cells":601},"Modafinil",{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":603,"activeCount":53},[],{"trials":605,"activeCount":53},[],{"trials":607,"activeCount":53},[608,618],{"nctId":609,"briefTitle":610,"status":517,"phases":611,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":617},"NCT00123370","Trial of Modafinil for Methamphetamine Dependence",[43],"2007-09","2006-07",87,[616],"Amphetamine Dependence",[600],{"nctId":619,"briefTitle":620,"status":517,"phases":621,"completion":612,"start":622,"enrollment":576,"conditions":623,"interventions":625},"NCT00123383","Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence",[43],"2005-07",[624],"Cocaine Dependence",[600],{"trials":627,"activeCount":53},[],{"trials":629,"activeCount":53},[],{"trials":631,"activeCount":53},[],{"intervention":633,"totalTrials":49,"cells":634},"nicotine transdermal patch\u002Flozenge",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":636,"activeCount":53},[],{"trials":638,"activeCount":53},[],{"trials":640,"activeCount":53},[641],{"nctId":642,"briefTitle":643,"status":107,"phases":644,"primaryCompletion":645,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":650},"NCT00350311","Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study",[43],"2008-04","2007-02",43,[27,649,29],"Obesity",[633],{"trials":652,"activeCount":53},[],{"trials":654,"activeCount":53},[],{"trials":656,"activeCount":53},[],{"intervention":658,"totalTrials":49,"cells":659},"D-Cycloserine",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":674,"PHASE4":676,"NA":678},{"trials":661,"activeCount":53},[],{"trials":663,"activeCount":53},[],{"trials":665,"activeCount":53},[666],{"nctId":667,"briefTitle":668,"status":107,"phases":669,"primaryCompletion":670,"completion":670,"start":671,"enrollment":8,"conditions":672,"interventions":673},"NCT00869765","Transcranial Direct Current Stimulation (tDCS) Augmentation by D-Cycloserine as a Treatment for Depression",[43],"2010-09","2009-04",[24,21],[658],{"trials":675,"activeCount":53},[],{"trials":677,"activeCount":53},[],{"trials":679,"activeCount":53},[],{"intervention":681,"totalTrials":49,"cells":682},"Escitalopram",{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":698,"PHASE4":700,"NA":702},{"trials":684,"activeCount":53},[],{"trials":686,"activeCount":53},[],{"trials":688,"activeCount":53},[689],{"nctId":690,"briefTitle":691,"status":107,"phases":692,"completion":693,"start":694,"enrollment":576,"conditions":695,"interventions":697},"NCT00156325","Escitalopram as a Mood Stabilizer for Bipolar II Disorder",[43],"2005-02","2004-02",[696],"Bipolar Disorders",[681],{"trials":699,"activeCount":53},[],{"trials":701,"activeCount":53},[],{"trials":703,"activeCount":53},[],{"intervention":592,"totalTrials":49,"cells":705},{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":716,"PHASE4":718,"NA":720},{"trials":707,"activeCount":53},[],{"trials":709,"activeCount":53},[],{"trials":711,"activeCount":53},[712],{"nctId":583,"briefTitle":584,"status":517,"phases":713,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":714,"interventions":715},[43],[590],[563,592],{"trials":717,"activeCount":53},[],{"trials":719,"activeCount":53},[],{"trials":721,"activeCount":53},[],{"intervention":723,"totalTrials":49,"cells":724},"CBD",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":740,"PHASE4":742,"NA":744},{"trials":726,"activeCount":53},[],{"trials":728,"activeCount":53},[],{"trials":730,"activeCount":53},[731],{"nctId":732,"briefTitle":733,"status":517,"phases":734,"primaryCompletion":735,"completion":586,"start":736,"enrollment":8,"conditions":737,"interventions":739},"NCT02083874","Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study",[43],"2014-09","2014-03",[738],"Cannabis Use Disorder",[723],{"trials":741,"activeCount":53},[],{"trials":743,"activeCount":53},[],{"trials":745,"activeCount":53},[],{"intervention":747,"totalTrials":49,"cells":748},"FMT infusions",{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":750,"activeCount":53},[],{"trials":752,"activeCount":53},[],{"trials":754,"activeCount":53},[755],{"nctId":756,"briefTitle":757,"status":107,"phases":758,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":765},"NCT01896635","Faecal Microbiota Transplantation in Ulcerative Colitis",[43],"2015-11","2016-08","2013-11",81,[764,202],"Ulcerative Colitis",[747],{"trials":767,"activeCount":53},[],{"trials":769,"activeCount":53},[],{"trials":771,"activeCount":53},[]]